Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
223 articles about Innovent Biologics
-
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
12/18/2023
Innovent Biologics, Inc. announces that results of a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications.
-
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
12/18/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and AnHeart Therapeutics ("AnHeart"), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review Designation[1] for the New Drug Application (NDA) of taletrectinib.
-
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
12/13/2023
Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.
-
IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
12/11/2023
IASO biotechnology and Innovent Biologics, Inc. announced the latest analysis results from the FUMANBA-1 study of Equecabtagene Autoleucel for the treatment of multiple myeloma in an oral presentation at the 65th American Society of Hematology Annual Meeting.
-
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
12/7/2023
Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.
-
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
12/5/2023
Innovent Biologics, Inc. announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma was published in The Journal of the American Medical Association (JAMA, IF=120.7).
-
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
12/1/2023
Innovent Biologics, Inc. announces the publication of updated clinical data of IBI351 monotherapy in non-small cell lung cancer and colorectal cancer at the European Society for Medical Oncology Asia Congress 2023, held during December 1-3 in Singapore.
-
Innovent's MSCI ESG Rating Upgraded to A
11/30/2023
Innovent Biologics, Inc. announces that the Company has been upgraded to 'A' according to Morgan Stanley Capital International's latest ESG rating, ranking at the forefront of the biotechnology industry.
-
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
11/24/2023
Innovent Biologics, Inc. announces that the New Drug Application for IBI351 has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China and granted Priority Review designation[1], for the treatment of patients with advanced non-small cell lung cancer harboring KRAS G12C mutation who have received at least one systemic therapy.
-
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
11/22/2023
Innovent Biologics, Inc. announces that full results from a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes were published in Diabetes Care.
-
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
11/22/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and AnHeart Therapeutics ("AnHeart") announce that the New Drug Application (NDA) for taletrectinib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.
-
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
11/22/2023
AnHeart Therapeutics and Innovent Biologics, Inc. today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
-
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
11/6/2023
Innovent Biologics, Inc. presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology 2023 Annual Meeting, including a Phase 2 clinical study of anti-VEGF and anti-complement bispecific fusion protein for neovascular age-related macular degeneration and a Phase 1 clinical study of anti-VEGF-A/Ang-2 bispecific antibody for diabetic macular edema.
-
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
9/29/2023
Innovent Biologics, Inc. and IASO Bio announced updated long-term follow-up data from two studies for BMCA CAR-T.
-
Innovent Announces 2023 Interim Results and Business Updates
8/23/2023
Innovent Biologics, Inc. announces its 2023 interim results and major company business updates.
-
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
8/16/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO®.
-
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
7/10/2023
RemeGen Co., Ltd., a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics .
-
IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
7/3/2023
IASO Biotechnology and Innovent Biologics, Inc. announced that China National Medical Products Administration has approved the New Drug Application for FUCASO, the world's first fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.
-
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
6/26/2023
Innovent Biologics, Inc. and RemeGen Co., Ltd., announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® with RC88, a novel mesothelin-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China.
-
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
6/12/2023
Innovent Biologics, Inc. announced that Phase 1 clinical data of the globally first anti-CD47/PD-L1 bispecific antibody IBI322 for the treatment of anti-PD-1-resistant patients with classic Hodgkin lymphoma was presented in oral presentation at the 28th Annual Meeting of the European Society of Hematology.